Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin

Novo's First Ph3 Icodec Trial (ONWARDS 1) Posted on CT.gov

Here is a brief preview of this blast: A new CT.gov record has been observed for Novo Nordisk's first Ph3 trial evaluating its QW insulin icodec insulin-naïve T2DM patients (ONWARDS 1). Novo appears to be branding the Ph3 program as "ONWARDS" in an effort to pay homage to the continued development story of insulin. In case you missed it, Lilly recently initiated two Ph2 trials for its QW insulin (LY3209590) in both T1DM and T2DM (previous FENIX insight). Below, FENIX provides an overview of the ONWARDS 1 trial as well as brief thoughts on Novo potentially providing additional clarity during its upcoming Q2 '20 earnings call on August 6, 2020.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.